Home Page

Welcome to the McGill International Tuberculosis Centre         

Hi All,

Yesterday’s UN High Level Meeting on TB went well. Everyone was happy that TB finally came out of shadows and got the attention of the UN. The political declaration was approved. But few heads of states attended the HLM, and that was disappointing. Out of the 190+ member states, only about 30 leaders attended the HLM. This was a historic opportunities for high TB burden countries to step up and show leadership. But heads of India, China, Brazil and Russia were missing. President Ramaphosa from South Africa was there, along with Minister Motsoaledi. SA really showed leadership and we were hoping for more countries to do that.

Canada was represented by Min Philpott, ITK leaders, Theresa Tam, Howard Njoo, and others. No new commitments were made. The Canadian delegation was rather subdued.

Most statements were general and no hard funding or other commitments were made. Notable exceptions were commitments from the USAID and DFID. USAID launched Global Accelerator to End TBhttps://www.usaid.gov/news-information/press-releases/sep-26-2018-usaid-administrator-mark-green-announces-new-approach-end-tuberculosis. DFID is giving funds to TB Alliance and Oxford for sequencing research.https://reliefweb.int/report/world/uk-leads-fight-against-increasing-drug-resistant-tb

I had a couple of opportunities to speak and videos are here:

http://webtv.un.org/search/general-assembly-high-level-meeting-on-the-fight-against-tuberculosis-multi-stakeholder-panel-2/5840619930001/?term=tuberculosis&lan=English&sort=date#t=1h17s

http://webtv.un.org/search/fight-to-end-tb-sdg-media-zone-at-the-73rd-session-of-united-nations-general-assembly/5840547299001/?term=&lan=english&page=4

Madhukar Pai, 
Director of the TB Centre
September 27, 2018

 

 

 

TB-oriented and other courses at the McGill Summer Institute in Infectious Diseases and Global Health

View website

 Recent Media Appearances

Congratulations to Dick Menzies:

THE NEW ENGLAND JOURNAL OF MEDICINE: Watch video of Dr. Menzies talking about his studies

- Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. Menzies D et al.N Engl J Med.August 2, 2018;379:440-453 Read article

- Safety and Side Effects of Rifampin versus Isoniazid in Children. Diallo T et al.N Engl J Med.August 2, 2018; 379:454-463 Read article

Read article featured in the Montreal Gazette

Read about the studies - MUHC Newsroom

THE LANCET: Watch video of Dr. Menzies talking about his study

- Treatment correlates of successful outcomes inpulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Ahmad N et al.The Lancet. September 8, 2018;392(10150):821-834 Read article

Read about this study in the McGill Reporter

Maziar Divangahi and Nargis KhanBeyond Killing Tuberculosis

Historically, our view of host defense against infection was that we must eliminate pathogens to eradicate disease. However, this perspective has recently been challenged as scientists have taken a lesson from plant biologists about an ancient strategy involving the ability to “tolerate” rather than “resist” infection to maintain health. This concept, referred to as “disease tolerance”, provides an opportunity to develop new strategies that mitigate the consequences of infection. Read more

Mitochondrial cyclophilin D regulates T cell metabolic responses and disease tolerance to tuberculosis - Science Immunology

Eva Kaufman, August winner 2018 of the Relève étoile Jacques-Genest award

Eva Kaufmann, a postdoctoral fellow in Medicine at McGill University, is the award winner of the Relève étoile Jacques-Genest award of the Fonds de recherche du Québec – Santé (FRQS).Her Award-winning publication: BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosisis published in Cell. Congratulations Eva! More details 

Great job at knowledge synthesis by TB Centre researchers:

Nature Review Primer on TB.

Just got designated as a ‘Highly cited paper’ by the Web of Science, meaning it is among the top 1% of papers of similar age in the field of clinical medicine! Read it here: http://go.nature.com/2Da2w2q 

The top-cited systematic reviews/meta-analyses in tuberculosis research:

McGill authors topped the rankings as first and corresponding authors in systematic reviews and meta-analyses in TB research.

​The 100 top-cited tuberculosis research studies: 

​According to a study, McGill researchers account for 6% of the world's best cited TB papers which is very high ranking! The 100 top-cited tuberculosis research https://www.atsjournals.org/doi/10.1164/rccm.201707-1489PPstudies (International Union Against Tuberculosis and Lung Disease) Download

Positions in Tuberculosis Research Available:

Selected Recent TB Articles/Publications

Our centre brings together over 20 investigators with expertise spanning epidemiology, policy setting, economic analyses, implementation research, meta-analyses,  qualitative research to basic science in microbiology, host genetics and immune response. 

The work is done both at an academic centre and with a number of collaborating groups around the world. On these pages, we introduce the faculty members who are members of our centre and describe our training programs for students.  Find out why our Centre is a world leader in the interdisciplinary study of TB and how we work together to unravel the many mysteries of this recalcitrant disease.

top of page